Two major factors which regulate tubuloglomerular feedback (TGF)-mediated constriction of the afferent arteriole are release of superoxide (O 2 Ϫ ) and nitric oxide (NO) by macula densa (MD) cells. MD O 2 Ϫ inactivates NO; however, among the factors that increase MD O 2 Ϫ release, the role of aldosterone is unclear. We hypothesize that aldosterone activates the mineralocorticoid receptor (MR) on MD cells, resulting in increased O 2 Ϫ production due to upregulation of cyclooxygenase-1 (COX-2) and NOX-2, and NOX-4, isoforms of NAD(P)H oxidase. Studies were performed on MMDD1 cells, a renal epithelial cell line with properties of MD cells. RT-PCR and Western blotting confirmed the expression of MR. Aldosterone (10 Ϫ8 mol/l for 30 min) doubled MMDD1 cell O 2 Ϫ production, and this was completely blocked by MR inhibition with 10 Ϫ5 mol/l eplerenone. RT-PCR, real-time PCR, and Western blotting demonstrated aldosterone-induced increases in COX-2, NOX-2, and NOX-4 expression. Inhibition of COX-2 (NS398), NADPH oxidase (apocynin), or a combination blocked aldosterone-induced O 2 Ϫ production to the same degree. These data suggest that aldosterone-stimulated MD O 2 Ϫ production is mediated by COX-2 and NADPH oxidase. Next, COX-2 small-interfering RNA (siRNA) specifically decreased COX-2 mRNA without affecting NOX-2 or NOX-4 mRNAs. In the presence of the COX-2 siRNA, the aldosterone-induced increases in COX-2, NOX-2, and NOX-4 mRNAs and O 2 Ϫ production were completely blocked, suggesting that COX-2 causes increased expression of NOX-2 and NOX-4. In conclusion 1) MD cells express MR; 2) aldosterone increases O 2 Ϫ production by activating MR; and 3) aldosterone stimulates COX-2, which further activates NOX-2 and NOX-4 and generates O 2 Ϫ . The resulting balance between O 2 Ϫ and NO in the MD is important in modulating TGF. tubuloglomerular feedback; renal hemodynamics; nitric oxide; kidney IN PATIENTS WITH MYOCARDIAL infarction or heart failure, aldosterone has been shown to promote cardiac inflammation. This is accompanied by increases in myocardial oxidative stress and release of inflammatory markers that include cyclooxygenase-2 (COX-2) (35). Aldosterone also causes nitric oxide (NO)-mediated vasodilation and superoxide (O 2 Ϫ ) release due to activation of NADPH oxidase (18) in cerebral and mesenteric arterioles. In cultured aortic endothelial cells, aldosterone has also been shown to induce O 2 Ϫ generation by activating NADPH oxidase (9).
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Tubuloglomerular glomerular feedback (TGF) is a critical mechanism for regulation of renal hemodynamics, NaCl excretion, and blood pressure (4, 39, 43) . Increasing tubular flow to the macula densa (MD) initiates a TGF signal causing constriction of the afferent arteriole, thus decreasing GFR. NO released from the MD modulates the TGF response, and O 2 Ϫ release from the MD will inactivate NO (10, 24, 25, 28) . Recently, we found that NOX-2 and NOX-4 isoforms of NAD(P)H oxidase are expressed in the rat MD and MMDD1 cells (46) . Although the role of aldosterone as a prooxidant and a proinflammatory agent has been established in the heart and in blood vessels, the prooxidant role of aldosterone in the MD is poorly understood. In addition, aldosterone activates mineralocorticoid receptors (MR), which have been found throughout the body but of particular interest to this paper, in the distal tubules, connecting tubules, and collecting ducts of the kidney (13, 29) . The presence of MR in the MD cells has not been reported. Our hypothesis is that aldosterone increases O 2 Ϫ production from MD cells acting through MR, and this is accompanied by increases in COX-2 production and NADPH oxidase via NOX-2 and NOX-4 production. These studies will greatly enhance our understanding of the role of aldosterone in regulating TGF and renal hemodynamics.
METHODS
All experiments were approved by the University of Mississippi Medical Center Animal Care and Use Committee before any procedures were performed. All reagents for cell culture were purchased from Invitrogen (Carlsbad, CA). All chemicals were purchased from Sigma (St. Louis, MO), except DMSO and lucigenin, which were obtained from Invitrogen.
MMDD1 cells. We used MMDD1 cells, a renal epithelial cell line with properties of MD cells, developed and kindly supplied by Dr. J. Schnermann (National Institutes of Health). These cells were derived from SV40 transgenic mice and have been shown to express wellknown MD markers, e.g., COX-2, neuronal NO synthase (nNOS), ROMK, and the Na-K-2Cl cotransporter (44) . In the present study, MMDD1 cells at passages 21-27 were routinely trypsinized and suspended in DMEM nutrient mixture-Ham's F-12, supplemented with 10% FBS, penicillin (100 U/ml), and streptomycin (100 g/ml). The cells were plated onto culture dishes and incubated at 37°C in a humidified atmosphere of 95% room air-5% CO 2. The medium was changed every 2 days, and once the cells reached confluence (typically in 2-3 days), the cells were ready for small-interfering RNA (siRNA) and O 2 Ϫ experiments.
Measurement of O 2
Ϫ with lucigenin. We measured O 2 Ϫ production in the MMDD1 cells using a lucigenin-enhanced chemiluminescence assay, as described previously (10) . Briefly, MMDD1 cells (10-cm dish) were washed by PBS two times, trypsinized from the dish, and kept in 12 Ϫ6 mol/l) was added to each of the samples, which were incubated for 30 min at 37°C with bubbling oxygen. From each group, a 0.5-ml sample was transferred into 1.6-ml polypropylene 8 ϫ 50-mm tubes (Evergreen Scientific), and then using a Sirius luminometer (Berthold Detection Systems, Pforzheim, Germany), O 2 Ϫ was measured following the manufacturer's instructions. Luminescence was measured for 10 s with a delay of 5 s.
RT-PCR for MMDD1 cells. Total RNA from the MMDD1 cells and mouse heart cells (as a positive control for the MR receptor) was extracted with an RNeasy Mini kit (Qiagen) following the manufacturer's instructions. One microgram of total RNA was reverse transcribed for 1 h at 42°C using 1 l random primer (3 g/l, Invitrogen) and an Ambion RETROscript kit (Ambion) following the manufacturer's instructions. In the protocol of RT-PCR for COX-2, NOX-2, and NOX-4, measured by specific subunit for each NOX isoform, the resultant RT product was then amplified by PCR by adding 1 l of the RT reaction, 1 mol/l of the gene-specific primers (Invitrogen), 2 l 10ϫ complete PCR buffer (Ambion), 1 l dNTP mix (Ambion), 2.5 mmol/l each, 0.2 l Super Taq, 5 U/l (Ambion), (1.2 l glycerol, 50% only for NOX-2 and NOX-4), and adding nuclear-free water (Invitrogen) to achieve a volume of 20 l. The mixed samples were heated to 94°C for 3 min and cycled at 94°C for 20 s, 59.4°C (COX-2), 56.6°C (NOX-2), 52.9°C (NOX-4) for 30 s, and 72°C for 30 s for 40 cycles. Final extension was for 8 min at 72°C. In the protocol for RT-PCR for the MR receptor, the mixed samples (50 l containing 1 l cDNA or 1 l mouse heart cDNA) using the described primers and using Titanium Taq polymerase were heated to 95°C for 2 min and cycled at 95°C for 40 s, annealing temperature 58°C for 40 s, and 72°C for 55 s for 40 cycles. Final extension was for 8 min at 72°C. The amplified products of RT-PCR were run on 1.4% (0.5% for MR receptor) agarose gels containing ethidium bromide (10 mg/ml, Invitrogen) and visualized under UV light. ␤-Actin, as a housekeeping gene, was set up as an internal loading control. A 100-bp DNA ladder marker was used to identify the molecular weight of the targeted DNA. Primer sequences and expected bands are listed in Table 1 .
Real-time PCR. Real-time PCR was used to quantify the mRNA level of the COX-2, NOX-2, and NOX-4 responses to aldosterone. Total RNA was isolated using an RNeasy Micro kit (Qiagen), and complementary DNA synthesis was carried out as described in the method for RT-PCR. Real-time PCR was performed in a C1000TM Thermal Cycler real-time PCR machine (Bio-Rad). ␤-Actin was used as a housekeeping gene.
Preparations for siRNA. COX-2 siRNA was used a predesigned product (Ambion). siRNA transfection was performed using a si-PORTTM Amine Transfection Agent (Ambion) according to the manufacturer's instructions. Scrambled siRNAs were synthesized and used as negative controls (Invitrogen). At 24 h before transfection, MMDD1 cells were transferred onto six-well plates (2 ϫ 10 5 cells/ well) with antibiotic-free medium. The cells were transfected with 10 nmol/l COX-2 siRNA duplex using an Amine Transfection Agent for 18 h in medium devoid of antibiotics. This procedure does not affect cell viability, measured with calcein as we described previously (26, 27) . The MMDD1 cells were washed once with PBS and grown in complete medium. Gene silencing was monitored by measuring RNA after incubation for 24 h. We added aldosterone (10 Ϫ8 mol/l) into each cell culture well and incubated it at 37°C for 30 min in a cell incubator before harvesting the MMDD1 cells.
Western blotting for MMDD1 cells. MMDD1 cell proteins were extracted with RIPA buffer plus a protease inhibitor cocktail. Protein concentration was measured using a Nanodrop instrument (Thermo Scientific). Cells were homogenized in RIPA buffer, centrifuged, and protein was measured using a Nanodrop spectrophotometer measuring absorption at 280 nm. Proteins extracted from MMDD1 cells in the amount of 100, 50, and 20 g were separated by 8% PAGE and transferred to polyvinylidene difluoride membranes, respectively. After the transfer, membranes were blocked at room temperature for 1 h with 1% fat-free dry milk in TTBS (10 mmol/l Tris·HCl, pH 7.5, 150 mmol/l NaCl, and 0.05% Tween 20) . The membranes were blocked and probed with the following primary antibodies, respectively: 1) MR, mixture of rMR 1-18 clone 1D5 (1:50 dilution) and MRN 365 clone 2D6 (1:100 dilution, overnight incubation); 2) COX-2 antibody (1:500 dilution, ab52237, Abcam); NOX-2 antibody (1:1,000 dilution, ab80508, Abcam); 3) NOX-4 antibody (horseradish peroxidase, 1:1,000 dilution, ab81967, Abcam); and 4) GAPDH (1:5,000, G8795, 4°C, overnight incubation, Sigma); this was followed by the secondary antibody (horseradish peroxidase goat anti-mouse IgG1, 10,000 dilution, 1-h incubation, Jackson ImmunoResearch Laboratories, West Grove, PA). The bands were visualized using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) and captured with a VersaDoc image analysis system (Bio-Rad).
Statistics. Data were analyzed as repeated measures over time or compared with a common control. We tested only the effects of interest, using ANOVA for repeated measures and a post hoc Fisher least significant difference test. The changes were considered to be significant if P Ͻ 0.05. Data are presented as means Ϯ SE. Figure 1A shows the RT-PCR results for the MR on MMDD1 cells. We used mouse myocardial cells as a positive control. Figure 1B shows the Western blot results of MR protein compared with the positive control. The results for the first time demonstrate the existence of mRNA and protein for MR in MMDD1 cells.
RESULTS

Mineralocorticoid receptors exist on MMDD1 cells.
Aldosterone acts through the MR to produce superoxide. We measured O 2 Ϫ levels in aldosterone-treated MMDD1 cells with and without the MR receptor inhibitor (eplerenone, 10 Ϫ5 mol/l) to confirm that the effect of aldosterone is mediated by the MR. As shown in Fig. 2 Fig. 3 shows that COX-2, NOX-2, and NOX-4 are expressed in the MMDD1 cells, and 
COX-2
F: 5=-cacagcctaccaaaacagcca-3= 99 R: 5=-gctcagttgaacgccttttga-3= NOX-2 F: 5=-ccagtgaagatgtgttcagct-3= 155 R: 5=-gcacagccagtagaagtagat-3= NOX-4 F: 5=-accagatgttgggcctaggattgt-3= 261 R: 5=-agttcactgagaagttcagggcgt-3= ␤-Actin F: 5=-aaccctaaggccaaccgtgaaaag-3= 241 R: 5=-tcatgaggtagtctgtcaggt-3= MR F: 5=-cacggctcttttgaagaagact-3= 90 R: 5=-atctgtttggtgtgtggagatg-3= F, forward; R, reverse; COX-2, cyclooxygenase-2; NOX-2 and NOX-4, isoforms of NAD(P)H oxidase; MR, mineralocorticoid receptor.
this result also verifies the efficacy of all of our primers to detect COX-2, NOX-2, and NOX-4.
Aldosterone enhances COX-2, NOX-2, and NOX-4 mRNA and protein expression. We used different aldosterone concentrations (1 and 10 nmol/l) to stimulate the MMDD1 cells for 30 min. The results in Fig. 4 show that exposing MMDD1 cells to aldosterone at different concentrations enhances COX-2, NOX-2, and NOX-4. Aldosterone at 10 Ϫ8 mol/l had the greatest effect (1.84-, 1.95-, and 1.82-fold increases in COX-2, NOX-2, and NOX-4 mRNA expression, respectively). Therefore, we used this concentration of aldosterone in the following experiment.
We measured protein levels of COX-2, NOX-2, and NOX4 with specific antibodies in MMDD1 cells stimulated with aldosterone (10 Ϫ8 mol/l) for 30 min. The results in Fig. 5 show that aldosterone significantly increased protein levels of COX-2, NOX-2, and NOX-4 by 1.78-, 2.31-, and 2.33-fold.
COX 
An siRNA knocked down COX-2 in MMDD1 cells. To study the function of COX-2 in aldosterone-induced O 2
Ϫ generation, we used an siRNA to silence COX-2. As shown in Fig. 7A , COX-2 siRNA significantly reduced its target COX-2 mRNA (51.8 Ϯ 1.2% vs. control). Scrambled siRNA had no significant effect on COX-2 mRNA (96.9 Ϯ 0.9% vs. control). Therefore, the results show that the COX-2 siRNA effectively knocked down COX-2 mRNA. Next, we determined whether this siRNA had any effect on NOX-2 or NOX-4 mRNA levels. Figure 7B shows that COX-2 siRNA did not affect NOX-2 mRNA expression (101.5 Ϯ 0.8% vs. control) or NOX-4 mRNA expression (101.8 Ϯ 1.0% vs. control). Scrambled Ϫ significantly (n ϭ 45, where n is the number of independent samples). Blocking MR with eplerenone (n ϭ 45) blocked aldosterone-induced increased in O 2 Ϫ . Eplerenone (n ϭ 48) had no effect on O 2 Ϫ in the absence of aldosterone compared with control group (n ϭ 44). *P Ͻ 0.05 vs. untreated cells, which were used as a control. Fig. 4 . Dose-response of aldosterone in mRNAs of COX-2, NOX-2, and NOX-4. Aldosterone at 10 Ϫ9 and 10 Ϫ8 mol/l for 30 min enhances mRNAs of COX-2, NOX-2, and NOX-4, and aldosterone at 10 Ϫ8 mol/l had the greater effect; n ϭ 3 for each group. *P Ͻ 0.05 vs. control. siRNA had no effect on NOX-2 mRNA expression (101.6 Ϯ 1.4% vs. control) or NOX-4 mRNA expression (106.1 Ϯ 5.0% vs. control). These data demonstrate the efficiency and specificity of COX-2 siRNA.
COX-2 siRNA blocked the effect of aldosterone on COX-2, NOX-2, and NOX-4 mRNAs and O 2
Ϫ generation. To study the role and their interactions between COX-2 and NOX-2 or NOX-4 in aldosterone-induced increases, we knocked down COX-2 and measured NOX-2 and NOX-4 levels. As shown in Fig. 8 , aldosterone (10 Ϫ8 mol/l) stimulated COX-2, NOX-2, and NOX-4 mRNA expression levels to 171.9 Ϯ 6.2, 207.4 Ϯ 7.8, and 199.8 Ϯ 10.9%, respectively. In the MMDD1 cells treated with COX-2 siRNA, aldosterone-induced increases in NOX-2 and NOX-4 mRNAs were blocked (109.1 Ϯ 1.6 and 107.1 Ϯ 0.8%, respectively), and COX-2 mRNA was reduced by 54.7 Ϯ 1.9%.
To study the role of COX-2 in aldosterone-induced O 2 Ϫ generation, we knocked down COX-2 and measured O 2 Ϫ . As shown in Fig. 9 
DISCUSSION
In this study, we found that the MR was expressed on MMDD1 cells. Aldosterone stimulates O 2 Ϫ production in MMDD1 cells mediated by MR. Both mRNA and protein levels of COX-2, NOX-2, and NOX-4 were upregulated by aldosterone. Knocking down COX-2 with an siRNA blocked aldosterone-induced increases in NOX-2 and NOX-4 as well as O 2 Ϫ production. Our data indicate that aldosterone stimulates COX-2, which further activates NOX-2 and NOX-4, resulting in enhanced O 2 Ϫ production. We report for the first time an MR on MMDD1 cells as confirmed by RT-PCR and Western blotting, and these cells demonstrated an elevation in O 2 Ϫ production when exposed to aldosterone. Blocking the MR with eplerenone completely COX-2 siRNA reduces COX-2 mRNA level significantly (n ϭ 17) compared with the untreated control cells (n ϭ 21). Scrambled siRNA (n ϭ 6) had no effect on COX-2 mRNA level. B: knocking down COX-2 mRNA with COX-2 siRNA did not affect the NOX-2 and NOX-4 mRNAs (no. of experiments for each group: control ϭ 9, NOX-2 ϭ 9, NOX-4 ϭ 12; COX-2 siRNA ϭ 12, NOX-2 ϭ 12, NOX-4 ϭ 12). Scrambled siRNA (NOX-2 ϭ 6, NOX-4 ϭ 5) had no effect. *P Ͻ 0.05 vs. control.
blocked the prooxidant effect of aldosterone. This suggests that aldosterone-induced O 2 Ϫ release from MMDD1 cells is mediated by the MR. PCR analysis clearly showed that COX-2, NOX-2, and NOX-4 were present in MMDD1 cells. COX-2 is profoundly expressed in the MD and is important in modulating TGF and renal hemodynamics (1, 6, 34, 42) . NOX-2 and NOX-4 are isoforms of NAD(P)H oxidase expressed in the MD (46) , which are important for salt and ANG II-induced O 2 Ϫ production (10, 46). However, the interaction between COX-2 and NOXs are not clear. We found that COX-2, NOX-2, and NOX-4 mRNAs and protein levels increased in MMDD1 cells exposed to aldosterone for 30 min. As shown in Fig. 6 , this prooxidant effect of aldosterone was eliminated with NS398, a blocker of COX-2; apocynin, a blocker of NADPH oxidase; and with a combination of NS398 and apocynin. These data indicate that COX-2 and NAD(P)H oxidase are the primary sources for aldosterone-induced O 2 Ϫ production in the MD. Similar O 2 Ϫ production was found in the presence of aldosterone combined with NS398, apocynin, or NS398ϩapocynin, suggesting a series effect of COX-2 and NAD(P)H oxidase.
Other new data in this study include a strong effect of COX-2 siRNA in inhibiting the aldosterone-induced increases in COX-2, NOX-2, and NOX-4 mRNAs in MMDD1 cells. A specific COX-2 siRNA effectively and selectively knocked down COX-2 mRNA in MMDD1 cells and did not change either NOX-2 mRNA or NOX-4 mRNA levels. These data indicate that COX-2 or a metabolite of COX-2 may increase transcription of NOX-2 and NOX-4 in MMDD1 cells upon stimulation by aldosterone. Limitations of the present study include how COX-2 is activated and whether it interacts with NOX isoforms. Molecular mechanisms, such as which COX-2-derived metabolite(s) stimulates NOX and the specific signaling pathway involved are the focus of future studies.
There are several potential sources of O 2 Ϫ in MD cells including uncoupled NOS, the electron transport system in mitochondria, xanthine oxidase, NAD(P)H oxidase, and COX. The primary sources for aldosterone-induced O 2 Ϫ in MD were COX-2, NOX-2, and NOX-4. Aldosterone clearly upregulated COX-2, NOX-2 ,and NOX-4, and inhibition of NAD(P)H oxidase or cyclooxygenase (Fig. 6 ) significantly decreased O 2 Ϫ production in MMDD1 cells. The data support a possible stimulatory effect of COX-2 on NOX-2 and NOX-4, since during aldosterone administration, a specific COX-2 siRNA not only decreased COX-2 mRNAs but also mRNAs of NOX-2 and NOX-4. Apocynin is a well-characterized inhibitor of NADPH oxidase. It acts by preventing serine phosphorylation of the cytosolic p47 phox subunit and blocking its assembly with gp91 phox in the cell membrane (8, 11, 33) . Of note, apocynin has recently been reported to have antioxidant effects that are independent of NOXs (17); thus it may be reducing O 2 Ϫ independently of NOX inhibition. Therefore, we cannot exclude the possibility that apocynin may affect the sources of O 2 Ϫ such as cytochrome P-450, mitochondria, xanthine oxidase, or uncoupled forms of NOS.
We designed these experiments to study the direct effects of aldosterone and tried to avoid the complex situation that occurs after superoxide generation. In some situations, NOX activation initiates production of reactive oxygen species (ROS), and other oxidase systems often amplify this initial response. ROS can also activate NOX enzymes and increase their own production in a positive feedback loop (5, 7, 22, 23, 32, 45) . We found that 30 min is the shortest time period that induces significant and consistent increases in superoxide.
Aldosterone has well-documented genomic and nongenomic effects in multiple tissues. It is believed that the genomic effects of aldosterone are mediated by the MR while nongenomic effects are independent of gene transcription (30) . In Madin-Darby canine kidney (MDCK) cells, which share properties with renal cortical collecting duct epithelium, there was within seconds after exposure to aldosterone an increase in intracellular calcium and sodium and an increased potassium flux (12) . This was likely caused by a nongenomic effect of aldosterone. In other kidney cell line, M-1 cells, aldosterone produced a rapid increase in intracellular calcium (14) . Aldosterone caused constriction of perfused afferent (at 1 nM aldosterone) and efferent arterioles (at 50 nM aldosterone) (2). This constriction was blocked by inhibitors of transcription and protein translation and sprironolactone, an MR inhibitor (2) . In endothelial cells, aldosterone at a concentration of 10 nM has been reported to induce superoxide generation from NAD(P)Hoxidase (21) . Aldosterone has recently been shown to increase superoxide production and induce cardiovascular injury in mineralocorticoid-induced hypertensive animals, whose effects were blocked by the administration of subpressor doses of MR antagonists as well as antioxidants and/or NAD(P)H oxidase inhibitors (3, 19, 36, 37, 41) . In the present study, our data indicate that even though the effect occurred in 30 min, the changes were due to genomic effects of aldosterone. First, aldosterone's effects on MMDD1 superoxide production were completely blocked with the MR inhibitor eplerenone. Second, increases in both mRNAs and protein levels of COX-2, NOX-2, and NOX-4 were significant in cells exposed to aldosterone. Third, the COX-2, NOX-2, and NOX-4 mRNA changes were specifically inhibited with a COX-2 siRNA. O 2 Ϫ release by MD cells can potentially increase afferent arteriolar constriction by two mechanisms. First, NO from nNOS opposes the TGF-mediated constriction of the afferent arteriole; therefore, an increase in MD O 2 Ϫ will scavenge NO and thus increase TGF (28, 31, 38, 43) . Second, a recent study was done in microdissected afferent arterioles with adherent tubular segments containing the MD. Microperfusion of the MD-containing segments at different flow rates induced TGF. Data obtained from inhibition of NO release from nNOS with 7-nitroindazole and inhibition of O 2 Ϫ with tempol and comparison with afferent arteriole-damaged endothelium showed that O 2 Ϫ directly constricted the afferent arteriole (25) .
The plasma aldosterone concentration is ϳ5.6 -13.9 nmol/l in human (20) and 0.8 -3.33 nmol/l in mice (16) . Even though the concentration of aldosterone in renal tubules is not clear, renal clearance studies have shown that aldosterone filters into the tubules, and ϳ90% of filtered aldosterone is reabsorbed primarily at the distal tubule (40) . In our preliminary study, we found that the MR is expressed in rat MD measured with immunohistochemistry and RT-PCR (unpublished data). We speculate that the MR in the MD is activated by aldosterone in the tubular lumen.
In summary, the MR has been found on MMDD1 cells, which mediates the increase in O 2 Ϫ production when exposed to aldosterone, and this prooxidant effect is blocked by eplerenone. COX-2, NOX-2, and NOX-4 mRNAs have been found in MMDD1 cells, and these mRNAs were significantly upregulated in the presence of aldosterone. The increase in O 2 Ϫ production in MMDD1 cells was blocked by inhibitors of COX-2 or NAD(P)H oxidase. In addition, in aldosteronestimulated MMDD1 cells, a selective COX-2 siRNA not only completely blocked aldosterone-induced increases in COX-2 but also NOX-2 and NOX-4 mRNAs, suggesting that COX-2 causes increased expression of NOX-2 and NOX-4. Therefore, aldosterone, acting through the MR, can increase O 2 Ϫ production in MD cells via stimulation of COX-2, NOX-2, and NOX-4. The interaction between O 2 Ϫ and NO in the MD will determine the bioavailability of NO, which is one of the most important factors that modulate TGF and GFR. Different amounts of O 2 Ϫ generated by the MD under different physiological and pathophysiological situations might contribute to alter TGF. This in turn will affect renal afferent arteriolar tone, which changes GFR and renal sodium excretion and thus blood pressure.
GRANTS
